Data / Research funding / Pennsylvania / Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc.: 13 NIH awards ($59.5M), fiscal years 2021 to 2026
Venatorx Pharmaceuticals, Inc. in Malvern, PA is funded under 13 NIH awards ($59.5M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- MBBKNBU5DCC6
- State
- Pennsylvania
Awards
13 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,835,693 | July 1, 2020 | August 31, 2026 | PEVEAR, DANIEL | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,313,540 | September 23, 2016 | March 31, 2026 | HENKEL, TIMOTHY | reporter.nih.gov |
| Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,328,779 | May 4, 2021 | April 30, 2027 | BOYD, STEVEN ARMEN | reporter.nih.gov |
| New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,603,680 | September 5, 2019 | August 31, 2025 | DAIGLE, DENIS MARC | reporter.nih.gov |
| Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | May 24, 2021 | April 30, 2025 | COBURN, GLEN ANDREW | reporter.nih.gov |
| Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,000,000 | March 10, 2022 | February 28, 2026 | LIU, BIN | reporter.nih.gov |
| Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,999,998 | June 7, 2023 | May 31, 2027 | COBURN, GLEN | reporter.nih.gov |
| Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,971,055 | August 22, 2018 | July 31, 2024 | BOYD, STEVEN ARMEN | reporter.nih.gov |
| Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,000,000 | April 1, 2024 | March 31, 2027 | UEHARA, TSUYOSHI | reporter.nih.gov |
| Advancement of antiviral inhibitors of chikungunya virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,000,000 | May 13, 2015 | April 30, 2023 | PEVEAR, DANIEL C | reporter.nih.gov |
| Discovery of antiviral inhibitors for the treatment of orthopoxvirus infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $600,000 | July 24, 2023 | December 31, 2025 | COBURN, GLEN | reporter.nih.gov |
| Discovery of inhibitors that target HBx for the treatment of chronic HBV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $506,623 | December 15, 2020 | November 30, 2023 | COBURN, GLEN ANDREW | reporter.nih.gov |
| Discovery of antiviral inhibitors of Ebola virus replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | July 15, 2020 | June 30, 2022 | COBURN, GLEN ANDREW | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 4 | $3,496,566 | 0 | $0 |
| 2024 | 7 | $14,298,969 | 0 | $0 |
| 2023 | 8 | $14,256,088 | 0 | $0 |
| 2022 | 8 | $16,218,246 | 0 | $0 |
| 2021 | 8 | $11,189,499 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 11 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 11 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 11 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 11 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 11 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 11 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 11 awards here |
Topics of its NIH awards
- Infectious Diseases
- Emerging Infectious Diseases
- Biodefense and Related Countermeasures
- Antimicrobial Resistance
- Orphan Drug
- Rare Diseases
- Biotechnology
- Translational Research
- Chronic Liver Disease and Cirrhosis
- Digestive Diseases
- Genetics
- Hepatitis
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.